AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 5 - (NewsRx.com & NewsRx.net) -- Ductal carcinoma in situ breast cancer runs a risk of recurrence if the immunohistological biomarkers for bcl-2 and estrogen and progesterone receptors are negative and the ERBB2 is positive.
According to published research from Australia, "The optimal management of ductal carcinoma in situ (DCIS) is controversial, due in part to our poor understanding of its natural history.
"We undertook to identify subgroups of DCIS based on the expression of biomarkers, which were related to the likelihood of clinical recurrence. Biomarker expression of a total of 95 DCIS lesions in a nested case-control study within a population-based cohort with up to 135 mo followup data (median 101 mo) was analyzed using immunohistochemistry.
"ERBB2 positivity and bcl-2, estrogen receptor (ER), and progesterone receptor (PR) negativity were individually associated with the risk of clinical recurrence.
"The predictive value of these biomarkers was independent of cytonuclear grade. ERBB2, bcl-2, ER and PR expression were conserved in the recurrent lesions, including ...
Source: HighBeam Research, Biological markers or lack thereof are predictive of clinical...